Shanghai Rightongene Biotechnology Co. Ltd. A (688217.SS) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE100005212

Price
21.45 CNY
Market cap
1.20 bn CNY
P/E (2025)
–
P/S (2025)
6.76
Dividend yield
0.00 %
Net margin
-28.42 %
Return on equity (ROE)
-5.96 %
Return on assets (ROA)
-5.69 %

Shanghai Rightongene Biotechnology Co. Ltd. A financials

Fiscal year20242025
Revenue242.31 m CNY177.26 m CNY
Gross profit180.59 m CNY133.62 m CNY
Operating income-9.26 m CNY-11.00 m CNY
EBIT-27.59 m CNY-50.54 m CNY
Net income-15.76 m CNY-50.38 m CNY
Diluted EPS – continuing operations-0.28 CNY-0.90 CNY

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Shanghai Rightongene Biotechnology Co. Ltd. A

Shanghai Rightongene Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products. The company provides gene and antigen testing for patients; and offers treatment plans, such as disease diagnosis, risk assessment, disease classification, targeted drug selection, and efficacy monitoring for for initial screening, follow-up, and re-examination of leukemia patients. It also offers molecular diagnostic kits for genes related to leukemia, lymphoma, solid tumors, and infectious diseases. In addition, it provides third-party medical testing services to various medical institutions, pharmaceutical companies, and individual patients, as well as gene testing research services to research hospitals, pharmaceutical companies, research institutions, and other third-party testing organizations. Shanghai Rightongene Biotechnology Co., Ltd. was founded in 2012 and is based in Shanghai, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.